# Simulations Plus Inc (SLP)

> Source: Nexqual · https://nexqual.com/SLP · data as of 2026-10-05 20:00 UTC · cite as "Nexqual, Simulations Plus Inc (SLP), nexqual.com/SLP" · informational, not investment advice.

**Price:** USD 18.5 (+0.00% on the day) · last close of Oct 5, 2026; US market closed, not a live price. Prev close 18.5 · day 18.49–18.5 · 52w 11.09–21.01 · market cap $374M · NMS

## Key facts
- Last four reported quarters (through May 31, 2026): revenue $82.1M, net income $8.1M (9.9% margin), free cash flow $24.5M (SEC filings).
- Valuation: P/E 46.2x.
- 1 of 80 tracked superinvestors hold SLP (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $815K; 0 not under a Rule 10b5-1 plan ($0K).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (2 analysts), mean target USD 18.5 (range 18.5–18.5).
- Next earnings: 2026-10-29, EPS estimate USD 0.12, revenue estimate $17.0M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $46.5M | $53.9M | $59.6M | $70.0M | $79.2M | $82.1M |
| Gross profit | $35.9M | $43.1M | $47.9M | $43.2M | $46.2M | — |
| Operating income | $11.3M | $14.9M | $8.7M | $6.1M | -$70.7M | $11.5M |
| Net income | $9.8M | $12.5M | $10.0M | $10.0M | -$64.7M | $8.1M |
| EPS (diluted) | $0.47 | $0.60 | $0.49 | $0.49 | -$3.22 | — |
| Free cash flow | $17.6M | $17.1M | $21.4M | $12.8M | $17.4M | $24.5M |
| Gross margin | 77.2% | 79.9% | 80.5% | 61.6% | 58.4% | — |
| Operating margin | 24.2% | 27.7% | 14.6% | 8.8% | -89.3% | 14.0% |
| Net margin | 21.1% | 23.2% | 16.7% | 14.2% | -81.7% | 9.9% |
| Revenue growth | +11.7% | +16.0% | +10.5% | +17.5% | +13.1% | — |
| Cash + short-term investments | $124M | $128M | $115M | $20.3M | $32.4M | — |
Fiscal years end Aug. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through May 31, 2026)
P/E 46.2x · P/S 4.6x · P/FCF 15.2x · P/B 2.7x · FCF yield 6.56% · Earnings yield 2.17%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold SLP. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $19.6M | Added +44.3% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
11 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan |
|---|---|---|---|---|---|---|
| 2026-08-03 | Dibella John Anthony Ii | Chief Revenue Officer | 1,000 | $18K | 1.2% | Yes |
| 2026-07-06 | Dibella John Anthony Ii | Chief Revenue Officer | 1,000 | $18K | 1.1% | Yes |
| 2026-07-01 | Woltosz Walter S | Director | 4,177 | $77K | 0.1% | Yes |
| 2026-06-16 | Fiedler-Kelly Jill | President, Services Solutions | 7,350 | $134K | 8.6% | Yes |
| 2026-06-15 | Fiedler-Kelly Jill | President, Services Solutions | 1,050 | $17K | 1.3% | Yes |
| 2026-06-03 | Dibella John Anthony Ii | Chief Revenue Officer | 1,000 | $17K | 1.1% | Yes |
| 2026-06-01 | Woltosz Walter S | Director | 15,000 | $261K | 0.5% | Yes |
| 2026-05-11 | Fiedler-Kelly Jill | President, Services Solutions | 1,000 | $17K | 1.3% | Yes |
| 2026-05-04 | Dibella John Anthony Ii | Chief Revenue Officer | 1,000 | $15K | 1.1% | Yes |
| 2026-05-04 | Woltosz Walter S | Director | 15,000 | $227K | 0.5% | Yes |
| 2026-04-15 | Dibella John Anthony Ii | Chief Revenue Officer | 1,000 | $13K | 1.1% | Yes |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

## Analysts
Consensus Hold (mean 3.00 on a 1–5 scale), 2 analysts; mean target USD 18.5 (low 18.5, high 18.5).

## Peers (Health Information Services)
CARL (Carlsmed, Inc.) USD 13.95 -3.59% · CTEV (Claritev Corporation) USD 23.86 +0.59% · NRC (NRC Health) USD 21.11 +4.66% · EVH (Evolent Health, Inc) USD 4.87 +5.87% · WEAV (Weave Communications, Inc.) USD 7.39 +0.27% · SOPH (SOPHiA GENETICS SA) USD 7.29 +2.82%

## More
Full page: https://nexqual.com/SLP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt